Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis

Nadkarni, Girish N., Ferrandino, Rocco, Chang, Alexander, Surapaneni, Aditya, Chauhan, Kinsuk, Poojary, Priti, Saha, Aparna, Ferket, Bart +2 more·2017·Diabetes Care

DOI 10.2337/dc17-1011

Cited by (188)

Items 101–188 of 188

Cardiorenal Syndrome in Type 2 Diabetes Mellitus – Rational Use of Sodium–glucose Cotransporter-2 Inhibitors
Sanjay Kalra, Hasan Aydin, Manisha Sahay, Sujoy Kumar Ghosh, Sundeep Ruder, MANGESH HARIHAR TIWASKAR, Gary Kilov, Kamal Kishor, Tiny Nair, Vikas Makkar et al. · 2020 · touchREVIEWS in Endocrinology
Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019
James Heyward, Jacob Christopher, Sudipa Sarkar, Jung‐Im Shin, Rita Rastogi Kalyani, G. Caleb Alexander · 2021 · Diabetes Obesity and Metabolism
Contrast-Induced Acute Kidney Injury in Patients with Heart Failure on Sodium–Glucose Cotransporter-2 Inhibitors Undergoing Radiocontrast Agent Invasive Procedures: A Propensity-Matched Analysis
Giulia Nardi, Enrico Marchi, Marco Allinovi, Gianmarco Lugli, Lucrezia Biagiotti, Francesca Maria Di Muro, Renato Valenti, Iacopo Muraca, Benedetta Tomberli, Niccolò Ciardetti et al. · 2024 · Journal of Clinical Medicine
Short-term effects of empagliflozin on preventing contrast induced acute kidney injury in patients undergoing percutaneous coronary intervention, a randomised trial
Zeinab Sadat Hosseini, Mohammad Javad Jamili, Behzad Ensan, Ghazaleh Donyadideh, Bahram Shahri, Hamid Eshraghi, Susan Darroudi, Mohsen Moohebati · 2025 · Scientific Reports
Is there any robust evidence showing that SGLT2 inhibitor use predisposes to acute kidney injury?
Sidar Çöpür, Abdullah Burak Yıldız, Carlo Basile, Katherine R. Tuttle, Mehmet Kanbay · 2022 · Journal of Nephrology
Residual Renal Risk in Diabetic Nephropathy Despite Contemporary Therapies
Reinhart Speeckaert, Charlotte Delrue, Marijn M. Speeckaert · 2026 · Journal of Clinical Medicine
Acute Kidney Injury and Subsequent Cardiovascular Disease: Epidemiology, Pathophysiology, and Treatment
Ming‐Jen Chan, Kathleen D. Liu · 2024 · Seminars in Nephrology
A Case of Severe Acute Kidney Injury Exacerbated by Canagliflozin in a Patient with Type 2 Diabetes
Kimya Hassani‐Ardakani, Mark L. Lipman, Denny P. Laporta, Oriana Hoi Yun Yu · 2019 · Case Reports in Endocrinology
Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review
Lisa Dubrofsky, Anand Srivastava, David Z.I. Cherney · 2020 · Canadian Journal of Kidney Health and Disease
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes—cardiovascular and renal benefits in patients with chronic kidney disease
T. Milder, S. Stocker, D. Samocha-Bonet, R. Day, J. Greenfield · 2019 · European Journal of Clinical Pharmacology
Epidemiology of acute kidney injury adverse events with SGLT2 inhibitors: A meta-analysis of observational cohort studies
Pierre Delanaye, André Jacques Scheen · 2021 · Diabetes Epidemiology and Management
SGLT2 Inhibitors’ Cardiovascular Benefits in Individuals Without Diabetes, Heart Failure, and/or Chronic Kidney Disease: A Systematic Review
Sajad Khiali, Mohammadreza Taban Sadeghi, Parvin Sarbakhsh, Naser Khezerlouy‐Aghdam, Afra Rezagholizadeh, Hila Asham, Taher Entezari‐Maleki · 2023 · The Journal of Clinical Pharmacology
Long‐term renal outcomes associated with sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis
Xiaodan Zhang, Zhen Zhong, Yanli Li, Wangen Li · 2020 · Diabetes/Metabolism Research and Reviews
Renoprotection with sodium‐glucose cotransporter‐2 inhibitors in children: Knowns and unknowns
Buchun Jiang, Zhiwen Cheng, Fei Liu, Qiuyu Li, Haidong Fu, Jianhua Mao · 2021 · Nephrology
Safety of SGLT2 Inhibitors in Three Chronic Diseases
Shiyao Ge, Ruobin Liu, Yu-Cheng Mao, Chang Geng, Hongfei Wang, Kai Song, Qing‐Bao Tian · 2023 · International Heart Journal
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence
Junhao Lv, Luying Guo, Rending Wang, Jianghua Chen · 2023 · Kidney Diseases
Renin-angiotensin-aldosterone system inhibition decreased contrast-associated acute kidney injury in chronic kidney disease patients
Yi‐Ting Chen, Chieh‐Kai Chan, Wenyi Li, Tao‐Min Huang, Tai‐Shuan Lai, Vin‐Cent Wu, Tzong‐Shinn Chu · 2020 · Journal of the Formosan Medical Association
Gliflozins in hypertension: basic mechanisms and clinical insights
Timo Rieg, Ruisheng Liu, Alexander Staruschenko · 2025 · American Journal of Physiology-Renal Physiology
Novel glucose-lowering drugs and the risk of acute kidney injury in routine care; the Stockholm CREAtinine Measurements (SCREAM) project
Jim Alkas, Alessandro Bosi, Arvid Sjölander, Peter F. Barany, Carl‐Gustaf Elinder, Edouard L. Fu, Juan Jesús Carrero · 2022 · Journal of Nephrology
Post‐initiation predictors of discontinuation of the sodium‐glucose cotransporter‐2 inhibitors: A comparative cohort study from the United Kingdom
Wajd Alkabbani, Baiju R. Shah, Arsène Zongo, Dean T. Eurich, Mhd Wasem Alsabbagh, John‐Michael Gamble · 2023 · Diabetes Obesity and Metabolism
Preventing all‐cause hospitalizations in type 2 diabetes with sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide ‐1 receptor agonists: A narrative review and proposed clinical approach
Meir Schechter, Matan Fischer, Ofri Mosenzon · 2022 · Diabetes Obesity and Metabolism
Evaluating the overall renal outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD)
Min-Jia Cao, Tingting Liang, Li Xu, Fang‐Hong Shi · 2025 · Diabetology & Metabolic Syndrome
An expanded prevention quality diabetes composite: Quantifying the burden of preventable hospitalizations for older adults with diabetes
Chin‐Lin Tseng, Orysya Soroka, LEONARD M. POGACH · 2018 · Journal of Diabetes and its Complications
Is the management of diabetes different in dialysis patients?
Sílvia Coelho · 2018 · Seminars in Dialysis
Acute kidney injury in Japanese type 2 diabetes patients receiving sodium–glucose cotransporter 2 inhibitors: A nationwide cohort study
Takeshi Horii, Yoichi Oikawa, Narumi Kunisada, Akira Shimada, Koichiro Atsuda · 2021 · Journal of Diabetes Investigation
Ketone bodies in renal function and diabetic kidney disease
Hamza Mechchate · 2025 · The Journal of Nutritional Biochemistry
Impact of sodium-glucose co-transporter 2 inhibitors on renal outcomes in patients of diabetes mellitus
Debdipta Bose, Miteshkumar Rajaram Maurya, Mahanjit Konwar · 2023 · Indian Journal of Pharmacology
Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting
Catherine B. Johannes, Daniel C. Beachler, J. Bradley Layton, Heather E. Danysh, RYAN M. ZIEMIECKI, Alejandro Arana, Jade Dinh, Ling Li, Brian Calingaert, Manel Pladevall et al. · 2022 · Drug Safety
Sulphonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: A population‐based cohort study
Nehal Islam, Pauline Reynier, Antonios Douros, Oriana Hoi Yun Yu, Kristian B. Filion · 2023 · Diabetes Obesity and Metabolism
A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
Lianglan Shen, Hongli Yang, Xingxing Fang, Huaxing Huang, Wubin Yao, Dongmei Chen, Yan Shen · 2021 · Diabetes Metabolic Syndrome and Obesity
Acute kidney injury events in patients with diabetes using sodium glucose transporter 2 inhibitors: a meta-analysis of cohort studies
Yanjing Shi, Shujie Dong, Yang Xu, Dongze Ji, Li Yang, Rongsheng Zhao · 2024 · Acta Diabetologica
Fenoldopam for Renal Protection in Cardiac Surgery: Pharmacology, Clinical Applications, and Evolving Perspectives
Giuseppe Cuttone, Luigi La Via, Giovanni Misseri, Giulio Geraci, Massimiliano Sorbello, Federico Pappalardo · 2024 · Journal of Clinical Medicine
Tubular Injury Causing Protracted Glycosuria Following Withdrawal of a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor: A Possible Role in the Development of Protracted Hypoglycemia and Ketoacidosis
Rika Hashi, Noritaka Fujiki, Toshihito Yagi · 2021 · The Tohoku Journal of Experimental Medicine
An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes
Genya Aharon‐Hananel, Itamar Raz · 2019 · Expert Opinion on Pharmacotherapy
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
Ashish Kataria, Christos Argyropoulos · 2022 · Springer eBooks
Prise de position de la Société Francophone du Diabète (SFD) : évaluation du rapport bénéfices-risques des inhibiteurs de SGLT2
Bernard Bauduceau, L. Bordier, J. Bringer, G. Chabrier, Bernard H. Charbonnel, Emmanuel Cosson, Patrice Darmon, B. Detournay, Pierre Fontaine, Pierre Gourdy et al. · 2019 · Médecine des Maladies Métaboliques
Efficacy and safety of Sodium-Glucose-Transporter-2 inhibitors in kidney transplant patients
Trond Geir Jenssen · 2021 · Current Opinion in Nephrology & Hypertension
Quand et comment utiliser les inhibiteurs de SGLT2 ou gliflozines en pratique clinique ? Un consensus proposé par la Société francophone du diabète (SFD), la Société française de cardiologie (SFC), le Collège national des cardiologues français (CNCF) et la Société francophone de néphrologie, dialyse et transplantation (SFNDT)
François Diévart, Patrice Darmon, Jean‐Michel Halimi, Samy Hadjadj, Denis Angoulvant, Gaëtan Prévost, Pierre Delanaye, Jean‐Marc Boivin · 2023 · Néphrologie & Thérapeutique
Angiotensin receptor-neprilysin inhibitor and sodium-dependent glucose cotransporter-2 inhibitor-associated renal injury: a pharmacovigilance study
Chen Chen, Bin Wu, Chenyu Zhang, Ting Xu · 2022 · Expert Opinion on Drug Safety
Initiation of peri-operative SGLT2 inhibitor reduces mortality and cardiovascular events after surgical aortic valve replacement
Jason Yan, Joseph McKinnerney, Taysir Al Janabi, Nikhilesh Korgaonkar, Rahul Kashyap · 2026 · The Cardiothoracic Surgeon
Assessment of effects of combination of SGLT2 inhibitors and renin–angiotensin–aldosterone system blockers on the renal functions of patients of diabetic kidney disease (SGRASS-DKD study)
Susovan Halder, Arnab Bhattacharyya, Shatavisa Mukherjee, Bhaswar Konar, Antareep Halder · 2024 · Journal of Diabetology
Hyaluronan Inhibition as a Therapeutic Target for Diabetic Kidney Disease: What Is Next?
Loay H. Salman, Laisel Martinez, Geovani Faddoul, Christina Manning, Karim Ali, Maya Salman, Roberto I. Vázquez-Padrón · 2023 · Kidney360
A Description of Acute Renal Failure and Nephrolithiasis Associated With Sodium–Glucose Co-Transporter 2 Inhibitor Use: A VigiBase Study
Ioana Frenț, Daniel‐Corneliu Leucuta, Camelia Bucșa, Andreea Maria Farcas, Florin Casoinic, Cristina Mogoșan · 2022 · Frontiers in Pharmacology
Angiotensin II Receptor Blockers but Not Angiotensin-Converting Enzyme Inhibitors Are Associated With a Reduced Risk of Acute Kidney Injury After Major Surgery
Shao‐Yu Yang, Tao‐Min Huang, Tai‐Shuan Lai, Nai‐Kuan Chou, Chun-Hao Tsao, Yiping Huang, Shuei‐Liong Lin, Yung‐Ming Chen, Vin‐Cent Wu, NSARF study group · 2021 · Frontiers in Pharmacology
Consensus to Reduce Withdrawal and Improve Adherence with SGLT2i: Consensus TWO SGLT2i Adherence Group
Nisha Singh, Akash Kumar Singh, Bijay Patni, Prabhat Agarwal, Manohar Kathige Nageshappa, Manish Kumar Prasad, Meena Chhabra, Noni Gopal Singha, M. Shunmugavelu, Arvind Gupta et al. · 2025 · Journal of the Association of Physicians of India
Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Patients With Diabetes and Chronic Kidney Disease (CKD): A Meta-analysis of Randomized Control Trials
Sidra Jamil, Arfa Zainab, Avneet Kaur Manjeet Singh Arora, Tanveer Ahamad Shaik, Vimal Khemani, Favour C Mekowulu, Yared N Aschalew, Saima Khan · 2022 · Cureus
Mise au point sur le profil de tolérance de la classe des inhibiteurs de SGLT2
Pierre Gourdy · 2019 · Médecine des Maladies Métaboliques
Acute Renal Failure With Cocaine and SGLT-2 Inhibitor
Snehal Shrivastava, Nishit Srivastava, Maria Alfonso-Jaume · 2019 · American Journal of Therapeutics
Akute Nierenschädigung – Update 2018
Daniel Patschan, Gerhard Anton Muller · 2018 · DMW - Deutsche Medizinische Wochenschrift
The contemporary landscape of cardiovascular optimization in type 2 diabetes: overcoming barriers to evidence-based use of newer antihyperglycemic agents
Konstantinos Malas, Salman Kazmi, Yu Mi Kang, Darren K. McGuire · 2025 · Expert Opinion on Pharmacotherapy
Evaluation of sodium‐glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics
Yi‐Fang Weng, Chung‐Yu Chen, Shang‐Jyh Hwang, Yaw‐Bin Huang · 2023 · The Kaohsiung Journal of Medical Sciences
Contrast-induced acute kidney injury; possible ameliorative effect of sodium-glucose co-transporter 2 inhibitors
Hamid Nasri · 2024 · Journal of Renal Endocrinology
Effect of SGLT2 inhibitors on kidney function of type 2 diabetes patients during Ramadan: A systematic review
Muhammad Aamir Waheed, Salah Suwileh, Khalid Rashid, Farrukh Ansar, Abdel-Naser Y Elzouki · 2024 · Qatar medical journal
Sodium-Glucose Cotransporter 2 Inhibitors in Patients Undergoing Coronary Angiography
Theera Phatikraisri, Massupa Krisem, Thamarath Chantadansuwan, Pichaya Tantiyavarong, Pisit Hutayanon, Nattachai Srisawat, Peerapat Thanapongsatorn · 2025 · Kidney360
Fundamentals of Epithelial Na+ Absorption
Alexander Staruschenko, Daria V. Ilatovskaya, Kenneth R. Hallows · 2015 · Springer eBooks
Effects of SGLT2 inhibitors on NSAID-associated acute kidney injury in type 2 diabetes: a claims-based cohort study
Yuki Kunitsu, Hiroyoshi Koide, Keiko Ikuta, Daiki Hira, Shunsaku Nakagawa, M. Tsuda, Shin-Ya Morita, Tomohiro Terada · 2026 · BMC Nephrology
The Association between SGLT2 Inhibitors Use and the Risk of Contrast Induced Acute Kidney Injury in Patients with Type 2 Diabetes
Hüseyin Ali Öztürk, Erdinç Gülümsek, Dilan Damla Öztürk, Fatih Necip Arıcı, Begüm Şeyda Avcı, Bektaş Işık, Mehmet Can Erişen, Berçem Berent Kaya, İrfan Alişan, Cahit Dincer et al. · 2025 · Cukurova Anestezi ve Cerrahi Bilimler Dergisi
SGLT2 Inhibitors and GLP1 Antagonists on Diabetes and Cardiovascular Disease
DAVID H. FITCHETT · 2023 · Contemporary cardiology
Comparative Safety Analysis of Empagliflozin in Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease versus Normal Kidney Function: A Nationwide Cohort Study in Korea
Ha Young Jang, In‐Wha Kim, Jung Mi Oh · 2023 · Pharmaceutics
Sodium-Glucose Cotransporter 2 Inhibitors' Mechanism of Action and Use in Kidney Transplantation Recipients: Extended Review and Update
Elmukhtar M. Habas, Ala M Habas, Islam Elzouki, Gamal B. Alfitori, Elmehdi Arrayes, Amnna Rayani, Kalifa Farfar, Eshrak Habas, Abdel-Naser Y Elzouki · 2024 · Journal of Diabetes and Endocrine Practice
SGLT-2 Inhibitors and Their Correlation With Kidney Stones. A Systematic Review
Bander J. Alshehri, Hani Shalabi · 2024 · Journal of Health and Rehabilitation Research
Risk of acute kidney injury in dapagliflozin users with type 2 diabetes: A nationwide propensity score‐matched cohort study in Korea
Hee‐Jin Kim, Heehyun Won, Suvin Park, Hui‐Eon Lee, Haerin Cho, Jeong Ah Kim, Na‐Young Jeong, HoJin Shin, Ye‐Jee Kim, Nam‐Kyong Choi · 2025 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
Promise, peril, and possible new treatment options incurred by sodium glucose co-transporter 2 (SGLT2) inhibitors: A precise review up to 2018
Md. Mahbubur Rahman Bhuiyan, Anawara Begum · 2019 · Obesity Medicine
Profil de tolérance des inhibiteurs de SGLT2 : le point en 2020
Patrice Darmon · 2020 · Médecine des Maladies Métaboliques
Evaluation of Sodium-Glucose Cotransporter-2 Inhibitor Use in an Underserved Ambulatory Care Population With Type 2 Diabetes
Ashley H. Meredith, Sydney Starks, Cassandra Etelamaki, Shelby Albertson, Jessica S. Triboletti, Lauren M. Pence, Todd A. Walroth, Kirsten McGrew, Jasmine D. Gonzalvo · 2021 · ADCES in Practice
Fundamentals of Epithelial Na+ Absorption
Alexander Staruschenko, Daria V. Ilatovskaya, Kenneth R. Hallows · 2020 · Physiology in health and disease
Protective Effect of SGLT2i on Contrast-Induced AKI after Angiography in Patients with Type 2 Diabetes Mellitus and Chronic Coronary Syndrome: A 6-Year Ambispective Cohort Study and Meta-Analysis
Zinan Zhao, Tianqi ZHANG, Yatong Zhang, Chao TIAN, Chenguang YANG, Ming Lan, Chi Zhang, Xin Hu, Pengfei JIN, Deping Liu · 2024 · Research Square
Safety Issues with Sodium-Glucose Cotransporter 2 Inhibitors: Clinical Considerations
Soo Kyung Lim · 2019 · Journal of Korean Diabetes
Therapeutic Options for Management of Diabetic Nephropathy
Holly Kramer, Sankar Dass Navaneethan · 2019 · Nephrology Self-Assessment Program
Extending the use of SGLT2 inhibitors from diabetic to non-diabetic kidney disease
Claire C. J. Dekkers · 2020
Acute Kidney Injury after Administering Dapagliflozin to a Diabetic Patient with Acute Cerebral Infarction
Changhyun Park, Eun Kyoung Lee, So Mi Kim, Jong Tae Cho, Do Hyun Lee, Jieun Lee, Ji Hyun Jeon · 2020 · Korean Journal of Medicine
Adding Pre-procedural Glycemia to the Mehran Score Enhances Its Ability to Predict Contrast-induced Acute Kidney Injury in Patients With and Without Diabetes Undergoing Percutaneous Coronary Intervention
Annunziata Nusca, Fabio Mangiacapra, Alessandro Sticchi, Giovanni Polizzi, Giulia D’Acunto, Elisabetta Ricottini, Rosetta Melfi, Paolo Gallo, Marco Miglionico, Sara Giannone et al. · 2020 · Research Square
Randomized Clinical Trial Replication Using Real-World Data for Comparative Cardiovascular and Safety Outcomes of Empagliflozin and Sitagliptin
Ha Young Jang, In‐Wha Kim, Jung Mi Oh · 2022 · Research Square
In Response
Sharon C. Peacock, Julie A. Lovshin, David Z.I. Cherney · 2018 · Anesthesia & Analgesia
Epidemiology and Outcomes for the Chronic Kidney Disease
Beini Lyu, Tripti Singh, Brad C. Astor · 2022 · Nephrology Self-Assessment Program
Possible amelioration impact of sodium-glucose cotransporter 2 inhibitors on cisplatin-induced renal toxicity; a mini-review on recent findings
Parisa Keshtgar, Leila Mahmoodnia, Samin Karamian · 2023 · Journal of Renal Injury Prevention
Inibitori del cotrasportatore sodio-glucosio di tipo 2 in pazienti sottoposti a trapianto renale
Aris Tsalouchos · 2023 · Giornale di Clinica Nefrologica e Dialisi
Empagliflozin causes nephrotoxicity in patients on guideline-directed medical therapy via urokinase-type plasminogen activator: An in silico approach
Anu Philip, Prarambh S. R. Dwivedi, C. S. Shastry, Basavaraj Utagi · 2023 · Annals of Phytomedicine An International Journal
Estimated glomerular filtration rate dip at sodium-glucose cotransporter 2 inhibitor initiation: Implications for practice in chronic kidney disease
Ying Fan, Niansong Wang · 2024 · Chinese Medical Journal
Sodium-Glucose Cotransporter 2 Inhibitors Decrease Contrast Induced Nephropathy In Patients With Heart Failure With Reduced Ejection Fraction Without Diabetes Mellitus
Fadime Koca, Mustafa Lütfullah Ardıç, Hazar Harbalıoğlu, Abdullah Eren Çetin, Berçem Berent Kaya, Mehmet Can Erişen, Hilmi Erdem Sümbül, Hasan Koca, Mevlüt Koç · 2025 · Bratislavské lekárske listy/Bratislava medical journal
Chronic Kidney Disease and Risk Management
2025 · American Diabetes Association eBooks
Comparative Safety of SGLT2 Versus DPP4 Inhibitors in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
Yue Li, Jie Chen, Yuying Gao, Jun Zhang, Siqiong Deng, Hao Li, Xin Zhang, Rui Li · 2026 · Diabetes Therapy
To Hold or Not to Hold, That Is the Question: Sick Day Medication Guidance as Routine Care
Sumeska Thavarajah · 2026 · American Journal of Kidney Diseases
Acute kidney injury risk with SGLT2 inhibitors versus sulfonylureas by baseline cardiorenal status in type 2 diabetes: A nationwide cohort study
Eonji Na, Hyeri Yang, Bonggi Kim, Sungho Won · 2026 · Research Square
Managing Advanced Diabetic Kidney Disease in the UAE: National Consensus Recommendations for Dialysis, Transplantation, and Emergencies
Alaaeldin M. Bashier, Mona Al Rukhaimi, Amna Khalifa Alhadari, Dawlat Hussein, Mohamed M. Hassanein, Elamin Ibrahim, Fauzia Rashid, Moayed Alhelfi, Dileep Naik Kumar, Fakhriya Juma Abdulla Alalawi et al. · 2026 · Journal of Diabetes and Endocrine Practice
GLIflozins in the prevention of contrast AssocIated NEphropathy: The GLICINE registry
Monica Verdoia, Filippo Zilio, Matteo Nardin, Marta Leverone, Jari Paternoster, Aron Faraguna, Emanuel Barnoffi, Domenico Lorusso, Gennaro Ciliberti, Tommaso Piva et al. · 2026 · International Journal of Cardiology
Therapeutic Repositioning of SGLT2 Inhibitors Using Real-World Data: A Scoping Review of Emerging Indications and Rare Diseases
Francesco De Felici, Serenella D'Agnese · 2026 · Research Square
Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of Current Evidence, Mechanisms, and Adverse Effects
Sam Woodworth, Robert Hayden · 2026 · Journal of Brown Hospital Medicine